186 related articles for article (PubMed ID: 38674098)
21. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
23. [Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
Pan BJ; Xu C; Ping GQ; Song GX; Zhang WM; Wang C; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):822-826. PubMed ID: 29224274
[No Abstract] [Full Text] [Related]
24. Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers.
Masili-Oku SM; Almeida BGL; Bacchi CE; Filassi JR; Baracat EC; Carvalho FM
Breast; 2017 Feb; 31():34-39. PubMed ID: 27810697
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
26. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
[No Abstract] [Full Text] [Related]
27. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
28. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer.
Adams TA; Vail PJ; Ruiz A; Mollaee M; McCue PA; Knudsen ES; Witkiewicz AK
Mod Pathol; 2018 Feb; 31(2):288-298. PubMed ID: 28984302
[TBL] [Abstract][Full Text] [Related]
29. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
[TBL] [Abstract][Full Text] [Related]
30. Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
Sanuki F; Mikami Y; Nishimura H; Fujita Y; Monobe Y; Nomura T; Taira N; Moriya T
Breast Cancer; 2023 Nov; 30(6):1041-1053. PubMed ID: 37642903
[TBL] [Abstract][Full Text] [Related]
31. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
Ali HR; Glont SE; Blows FM; Provenzano E; Dawson SJ; Liu B; Hiller L; Dunn J; Poole CJ; Bowden S; Earl HM; Pharoah PD; Caldas C
Ann Oncol; 2015 Jul; 26(7):1488-93. PubMed ID: 25897014
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer.
Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S
Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162
[TBL] [Abstract][Full Text] [Related]
34. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
[TBL] [Abstract][Full Text] [Related]
35. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
[TBL] [Abstract][Full Text] [Related]
36. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
38. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
[TBL] [Abstract][Full Text] [Related]
39. [Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers].
Yang YL; Song YM; Xue HQ; Sun H; Li YQ; Qian XL; Jiao J; Li KP; Zhang H; Guo XJ
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):165-169. PubMed ID: 36781238
[No Abstract] [Full Text] [Related]
40. Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.
Kim NI; Park MH; Cho N; Lee JS
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):246-256. PubMed ID: 35384874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]